CYP17A1
CYP17A1 (cytochrome P450 family 17 subfamily A member 1, also known as P450C17, CYP17, CPT7 and S17AH) is an endoplasmic reticulum cytochrome P450 monooxygenase. It carries both 17-alpha-hydroxylase and 17,20-lyase activities and sits at a key branch point of corticoid and androgen biosynthesis. Browse Assay Genie's current range of CYP17A1 research reagents below, or read on for the biology behind the target.
CYP17A1 is a cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis. It catalyses 17-alpha hydroxylation of C21 steroids, a step common to both pathways. Pregnenolone and progesterone are hydroxylated to their 17-alpha hydroxy metabolites, which are precursors of cortisol in the adrenal glucocorticoid pathway. A second oxidative step, required only for androgen synthesis, cleaves the C17-C20 bond to form the C19 steroids dehydroepiandrosterone (DHEA) and androstenedione.
The enzyme also has 16-alpha hydroxylase activity. It 16-alpha hydroxylates 17-alpha hydroxy pregnenolone, followed by C17-C20 cleavage to give 16-alpha-hydroxy DHEA, and it 16-alpha hydroxylates androgens, which is relevant for estriol synthesis. Mechanistically, it uses molecular oxygen, inserting one oxygen atom into the substrate and reducing the second to water, with two electrons supplied by NADPH through cytochrome P450 reductase (CPR). Together, these activities make it a key enzyme in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens and oestrogens.
The CYP17A1 gene belongs to the cytochrome P450 superfamily, whose members catalyse many reactions in drug metabolism and in the synthesis of cholesterol, steroids and other lipids. The protein localises to the endoplasmic reticulum and microsomal membranes. Previous names include P450C17 and cytochrome P450 subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia. Mutations in the gene are associated with isolated steroid-17 alpha-hydroxylase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism and adrenal hyperplasia. Mouse and rat orthologs are both named Cyp17a1.
CYP17A1 hydroxylates pregnenolone and progesterone and then cleaves the C17-C20 bond, making it central to studies of corticoid and androgen production.
The 17-alpha hydroxy intermediates it produces are precursors of cortisol, so the enzyme is relevant to adrenal glucocorticoid biosynthesis research.
Mutations in the gene are associated with 17-alpha-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism and adrenal hyperplasia, which supports disease-focused investigation.
CYP17A1 receives electrons from NADPH via cytochrome P450 reductase, making it a model for studying P450 monooxygenase mechanism.
CYP17A1 is a cytochrome P450 monooxygenase that 17-alpha hydroxylates pregnenolone and progesterone, then cleaves the C17-C20 bond to form DHEA and androstenedione. It therefore supports both corticoid and androgen biosynthesis, and also shows 16-alpha hydroxylase activity.
CYP17A1 is also called P450C17, CYP17, CPT7 and S17AH. Its UniProt name is steroid 17-alpha-hydroxylase/17,20 lyase, and its enzyme classification is EC 1.14.14.19. Older names refer to cytochrome P450 subfamily XVII, adrenal hyperplasia.
Mutations in CYP17A1 are associated with isolated steroid-17 alpha-hydroxylase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism and adrenal hyperplasia. Orthologs exist in mouse and rat, both named Cyp17a1; check the datasheet of any product for its validated reactivity.
Other cytochrome P450 enzymes, including steroidogenic and drug-metabolising family members, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P05093; product specifications from Assay Genie datasheets.